Regadenoson Cardiac Stress Test-Induced Takotsubo Cardiomyopathy: A Case Report.

cardiac stress test regadenoson takotsubo cardiomyopathy

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
07 May 2020
Historique:
entrez: 13 6 2020
pubmed: 13 6 2020
medline: 13 6 2020
Statut: epublish

Résumé

A 79-year-old female presented with acute left-sided chest pain with shortness of breath; she was afebrile and vitally stable. She had a mildly elevated troponin (0.11 ng/mL). Her N terminal pro B-type natriuretic peptide (NT-proBNP) was 7053 pg/mL and electrocardiography (ECG) showed nonspecific ST, T wave changes. Transthoracic echocardiogram (TTE) revealed an ejection fraction (EF) of 65-70%. She was diagnosed with a non-ST elevation myocardial infarction (NSTEMI) and underwent a nuclear stress test, which was negative for ischemia with no left ventricular motion abnormality and an EF of 73%. The patient developed acute respiratory failure following the Lexiscan (Astellas Pharma US, Northbrook, IL) and had to be intubated. A chest X-ray showed pulmonary edema, and transesophageal echocardiography (TEE) revealed a severely reduced EF of 25% with a new anterior wall motion abnormality. Left heart catheterization showed no significant coronary artery disease. Ventriculogram revealed a significantly reduced EF of 30% with apical akinesia. These findings were compatible with myocardial infarction with non-obstructive coronary arteries (MINOCA), likely secondary to regadenoson, which presented like takotsubo cardiomyopathy (TCM). Her condition gradually improved and the follow-up echo revealed baseline EF without symptoms of heart failure. In conclusion, takotsubo cardiomyopathy can be a potential complication from Lexiscan and can present as new-onset heart failure after the stress test.

Identifiants

pubmed: 32528746
doi: 10.7759/cureus.8004
pmc: PMC7279683
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e8004

Informations de copyright

Copyright © 2020, Farid et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cardiol J. 2012;19(1):92-4
pubmed: 22298176
Circulation. 2008 Jul 22;118(4):397-409
pubmed: 18645066
N Engl J Med. 2015 Sep 3;373(10):929-38
pubmed: 26332547
Jpn Circ J. 2000 Feb;64(2):156-9
pubmed: 10716533
Am Heart J. 2012 Jul;164(1):66-71.e1
pubmed: 22795284
Chest. 2007 Sep;132(3):809-16
pubmed: 17573507
Am J Cardiovasc Dis. 2013;3(1):53-9
pubmed: 23459262
Eur J Echocardiogr. 2006 Jan;7(1):53-61
pubmed: 16182610
Int J Cardiol. 2008 Mar 14;124(3):283-92
pubmed: 17651841
Pharmacotherapy. 2015 Dec;35(12):1117-23
pubmed: 26684552
BMJ Case Rep. 2017 Aug 10;2017:
pubmed: 28798245
Circulation. 2017 Jun 13;135(24):2426-2441
pubmed: 28606950

Auteurs

Saira Farid (S)

Internal Medicine, MedStar Washington Hospital Center - Georgetown University Hospital, Washington, D.C., USA.

Muhammad Ahsan (M)

Cardiology, Mercy Health - St. Vincent Medical Center, Toledo, USA.

Hector M Garcia-Garcia (HM)

Cardiology, MedStar Washington Hospital Center, Washington, D.C., USA.

Classifications MeSH